Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110)
Public ClinicalTrials.gov record NCT00062582. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The aim of the study is to compare the effect of roflumilast and placebo on the lung function in patients with COPD.
Study identification
- NCT ID
- NCT00062582
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,000 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2003
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Nov 22, 2016
Started 2003
United States locations
- U.S. sites
- 32
- U.S. states
- 32
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ALTANA Pharma | Cities in Alabama | Alabama | — | — |
| ALTANA Pharma | Cities in Arizona | Arizona | — | — |
| ALTANA Pharma | Cities in California | California | — | — |
| ATLANA Pharma | Cities in Colorado | Colorado | — | — |
| ALTANA Pharma | Cities in Conneticut | Connecticut | — | — |
| ALTANA Pharma | Cities in Delaware | Delaware | — | — |
| ALTANA Pharma | Cities in Florida | Florida | — | — |
| ALTANA Pharma | Cities in Georgia | Georgia | — | — |
| ALTANA Pharma | Cities in Idaho | Idaho | — | — |
| ALTANA Pharma | Cities in Indiana | Indiana | — | — |
| ALTANA Pharma | Cities in Iowa | Iowa | — | — |
| ALTANA Pharma | Cities in Kansas | Kansas | — | — |
| ALTANA Pharma | Cities in Kentucky | Kentucky | — | — |
| ALTANA Pharma | Cities in Louisiana | Louisiana | — | — |
| ALTANA Pharma | Cities in Maryland | Maryland | — | — |
| ALTANA Pharma | Cities in Michigan | Michigan | — | — |
| ALTANA Pharma | Cities in Missouri | Missouri | — | — |
| ALTANA Pharma | Cities in Nebraska | Nebraska | — | — |
| ALTANA Pharma | Cities in Nevada | Nevada | — | — |
| ALTANA Pharma | Cities in New Jersey | New Jersey | — | — |
| ALTANA Pharma | Cities in New York | New York | — | — |
| ALTANA Pharma | Cities in North Carolina | North Carolina | — | — |
| ALTANA Pharma | Cities in Ohio | Ohio | — | — |
| ALTANA Pharma | Cities in Oregon | Oregon | — | — |
| ALTANA Pharma | Cities in Pennsylvania | Pennsylvania | — | — |
| ALTANA Pharma | Cities in Rhode Island | Rhode Island | — | — |
| ALTANA Pharma | Cities in South Carolina | South Carolina | — | — |
| ALTANA Pharma | Cities in Texas | Texas | — | — |
| ALTANA Pharma | Cities in Utah | Utah | — | — |
| ALTANA Pharma | Cities in Virginia | Virginia | — | — |
| ALTANA Pharma | Cities in Washington | Washington | — | — |
| ALTANA Pharma | Cities in West Virginia | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00062582, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 22, 2016 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00062582 live on ClinicalTrials.gov.